Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. (Q34269292)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Christos Markopoulos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

5

Vernon K Sondak

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

3

Christine S Falk

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Helen Gogas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

John M Kirkwood

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Dimosthenis Tsoutsos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Alexandros Stratigos

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Dimitrios Pectasides

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Maria Spyropoulou-Vlachou

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

English

0 references

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

4326-4333

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

Peptides presented in vivo by HLA-DR in thyroid autoimmunity.

5 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

The HLA system. Second of two parts

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

HLA associations in the antitumor response against malignant melanoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

HLA and disease associations: detecting the strongest association

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

What is the basis for HLA-DQ associations with autoimmune disease?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2970916

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma

28 October 2018

1 reference

12 December 2020

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

12 December 2020

Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients

1 reference

12 December 2020

Molecular genetic analysis of HLA-DR and -DQ alleles in Spanish patients with melanoma

1 reference

12 December 2020

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690

1 reference

12 December 2020

Nomenclature for factors of the HLA system, 2002

1 reference

12 December 2020

1 reference

12 December 2020

HLA-DRB101 subtyping by allele-specific PCR amplification: A sensitive, specific and rapid technique

1 reference

12 December 2020

HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2)

1 reference

12 December 2020

HLA-DQB1*0301 association with increased cutaneous melanoma risk

1 reference

12 December 2020

HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2

1 reference

12 December 2020

Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?

1 reference

12 December 2020

Nonparametric Estimation from Incomplete Observations

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.25211

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCR.25211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20549830%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

PubMed publication ID

20549830

1 reference